Liraglutide, a human glucagon-like peptide-1 analogue, plays a role in reducing body weight in the patients with type 2 diabetes / 中华内分泌代谢杂志
Chinese Journal of Endocrinology and Metabolism
; (12): 703-706, 2011.
Article
in Zh
| WPRIM
| ID: wpr-424193
Responsible library:
WPRO
ABSTRACT
Obesity is associated with numerous metabolic abnormalities, including insulin resistance and type 2 diabetes. Losing weight is an effective way of improving insulin sensitivity, thus decreasing the risk of obesityassociated diabetes and chronic cardiovascular disease. There is evidence that Liraglutide, as a human glucagon-like peptide-1 ( GLP-1 ) analogue, either using alone or combining with other glucose-lowering drugs, has effect on improving glycemic control, protecting β-cell function, and reducing body weight via inhibiting feeding behavior and delaying gastrointestinal motility. Therefore, liraglutide is a new option for treating type 2 diabetes patients.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Chinese Journal of Endocrinology and Metabolism
Year:
2011
Type:
Article